A meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with aflibercept

Journal of Ophthalmology

Volumn 2016, Issue , 2016, Pages

  Seguin Greenstein, Sophie ^a,b   Lightman, Sue ^a,b,c   Tomkins Netzer, Oren ^a,b,c,d  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84962059540     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2016/4095852     Document Type: Article

References (38)

1. L. S. Lim, P. Mitchell, J. M. Seddon, F. G. Holz, and T. Y. Wong, "Age-related macular degeneration, " The Lancet, vol. 379, no. 9827, pp. 1728-1738, 2012.
2. F. L. Ferris III, S. L. Fine, and L. Hyman, "Age-related macular degeneration and blindness due to neovascular maculopathy, " Archives of Ophthalmology, vol. 102, no. 11, pp. 1640-1642, 1984.
3. H. Takahashi and M. Shibuya, "Thevascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions, " Clinical Science, vol. 109, no. 3, pp. 227-241, 2005.
4. N. Ferrara, H.-P. Gerber, and J. LeCouter, "Thebiology ofVEGF and its receptors, " Nature Medicine, vol. 9, no. 6, pp. 669-676, 2003.
5. D. M. Brown, P. K. Kaiser, M. Michels, et al., "Ranibizumab versus verteporfin for neovascular age-related macular degeneration, " The New England Journal of Medicine, vol. 355, no. 14, pp. 1432-1444, 2006.
6. J. S. Heier, D. M. Brown, V. Chong, et al., "Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration, " Ophthalmology, vol. 119, no. 12, pp. 2537-2548, 2012.
7. P. J. Rosenfeld, D. M. Brown, J. S. Heier, et al., "Ranibizumab for neovascular age-related macular degeneration, " The New England Journal ofMedicine, vol. 355, no. 14, pp. 1419-1431, 2006.
8. D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration, " The New England Journal of Medicine, vol. 364, no. 20, pp. 1897-1908, 2011.
9. Diabetic Retinopathy Clinical Research Network, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema, " The New England Journal ofMedicine, vol. 372, no. 13, pp. 1193-1203, 2015.
10. A. Liberati, D. G. Altman, J. Tetzlaff, et al., "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, " The British Medical Journal, vol. 339, Article ID b2700, 2009.
11. G. Wells, L. Brodsky, D. OConnell, and J. Robertson, "Evaluation of the Newcastle-Ottawa Scale (NOS): an assessment tool for evaluating the quality of non-randomized studies, " in Proceedings of the 11th Cochrane Colloquium: Evidence, Health Care and Culture, Barcelona, Spain, October 2003.
12. M. Bawor, B. B. Dennis, R. Anglin, M. Steiner, L. Thabane, and Z. Samaan, "Sex differences in outcomes of methadone maintenance treatment for opioid addiction: a systematic review protocol, " Systematic Reviews, vol. 3, article 45, 2014.
13. B. J. Becker, "Synthesizing standardized mean change measures, " British Journal of Mathematical and Statistical Psychology, vol. 41, pp. 257-278, 1988.
14. M. W. Lipsey and D. B. Wilson, Practical Meta Analysis, SAGE Publications, 2001.
15. M. Borenstein, L. V. Hedges, J. P. T. Higgins, and H. R. Rothstein, Introduction to Meta-Analysis, JohnWiley & Sons, 2009.
16. P. J. Ferrone, F. Anwar, J. Naysan, et al., "Early initial clinical experience with intravitreal aflibercept for wet age-related macular degeneration, " British Journal of Ophthalmology, vol. 98, supplement 1, pp. i17-i21, 2014.
17. H. Cho, C. P. Shah, M. Weber, and J. Heier, "Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab, " British Journal of Ophthalmology, vol. 97, no. 8, pp. 1032-1035, 2013.
18. C. A. Arcinue, F. Ma, G. Barteselli, L. Sharpsten, M. L. Gomez, and W. R. Freeman, "One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration, " American Journal of Ophthalmology, vol. 159, no. 3, pp. 426-436. e2, 2015.
19. C. K. Chan, A. Jain, S. Sadda, and N. Varshney, "Optical coherence tomographic and visual results at six months after transitioningto aflibercept for patientson prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis), " Transactions of the American Ophthalmological Society, vol. 112, pp. 160-198, 2014.
20. M. R. Thorell, R. P. Nunes, G. W. Chen, et al., "Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD, " Ophthalmic Surgery Lasers and Imaging Retina, vol. 45, no. 6, pp. 526-533, 2014.
21. R. DerSimonian and R. Kacker, "Random-effects model for meta-analysis of clinical trials: an update, " Contemporary Clinical Trials, vol. 28, no. 2, pp. 105-114, 2007.
22. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, "Measuring inconsistency in meta-analyses, " British Medical Journal, vol. 327, no. 7414, pp. 557-560, 2003.
23. M. Egger, G. D. Smith, M. Schneider, and C. Minder, "Bias in meta-analysis detected by a simple, graphical test, " British Medical Journal, vol. 315, no. 7109, pp. 629-634, 1997.
24. N. Kumar, M. Marsiglia, S. Mrejen, et al., "Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration, " Retina, vol. 33, no. 8, pp. 1605-1612, 2013.
25. B. Bakall, J. C. Folk, H. C. Boldt, et al., "Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab, " American Journal of Ophthalmology, vol. 156, no. 1, pp. 15-22. e1, 2013.
26. M. Gharbiya, L. Iannetti, F. Parisi, U. DeVico, M. L. Mungo, and M. Marenco, "Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-relatedmacular degeneration, " BioMed Research International, vol. 2014, Article ID 273754, 7 pages, 2014.
27. W. B. Messenger, J. P. Campbell, A. Faridi, et al., "Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration, " British Journal of Ophthalmology, vol. 98, no. 9, pp. 1205-1207, 2014.
28. C. C. Wykoff, D. M. Brown, M. E. Maldonado, and D. E. Croft, "Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial), " British Journal of Ophthalmology, vol. 98, no. 7, pp. 951-955, 2014.
29. A. A. Chang, H. Li, G. K. Broadhead, et al., "Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration, " Ophthalmology, vol. 121, no. 1, pp. 188-192, 2014.
30. R. P. Singh, S. Srivastava, J. P. Ehlers, R. Bedi, A. P. Schachat, and P. K. Kaiser, "A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis, " British Journal of Ophthalmology, vol. 98, supplement 1, pp. i22-i27, 2014.
31. D. S. Grewal, M. K. Gill, D. Sarezky, A. T. Lyon, and R. G. Mirza, "Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results, " Eye, vol. 28, no. 7, pp. 895-899, 2014.
32. J. Pinheiro-Costa, J. M. Costa, J. N. Beato, et al., "Switch to aflibercept in the treatment of neovascular amd: one-year results in clinical practice, " Ophthalmologica, vol. 233, no. 3-4, pp. 155-161, 2015.
33. F. Forooghian, C. Cukras, C. B. Meyerle, E. Y. Chew, and W. T. Wong, "Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration, " Retina, vol. 29, no. 6, pp. 723-731, 2009.
34. S. Binder, "Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?" British Journal of Ophthalmology, vol. 96, no. 1, pp. 1-2, 2012.
35. J. L. Gasperini, A. A. Fawzi, A. Khondkaryan, et al., "Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation, " British Journal ofOphthalmology, vol. 96, no. 1, pp. 14-20, 2012.
36. N. Kumar, S. Mrejen, A. T.-C. Fung, M. Marsiglia, B. K. Loh, and R. F. Spaide, "Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration, " Ophthalmology, vol. 120, no. 2, pp. 334-341, 2013.
37. J. E. Grunwald, E. Daniel, J. Huang, et al., "Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials, " Ophthalmology, vol. 121, no. 1, pp. 150-161, 2014.
38. J. E. Grunwald, M. Pistilli, G. Ying, M. G. Maguire, E. Daniel, and D. F. Martin, "Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials, " Ophthalmology, vol. 122, no. 4, pp. 809-816, 2015.